Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa F Newcomb

Showing results (31-40 of 62) with videos related to

Pageof 7
Sort By:
The Journal of Urology|April 30, 2025
Magnetic Resonance Imaging at Second Surveillance Biopsy After Diagnosis in Patients With Grade Group 1 Prostate Cancer in the Canary Prostate Active Surveillance StudyMeera R Chappidi, Lisa F Newcomb, Yingye Zheng, et al.
Cancer|September 13, 2021
Treatment in the absence of disease reclassification among men on active surveillance for prostate cancerPeter S Kirk, Kehao Zhu, Yingye Zheng, et al.
The Journal of Urology|July 13, 2022
Impact of Prostate Health Index Results for Prediction of Biopsy Grade Reclassification During Active SurveillanceChristopher P Filson, Kehao Zhu, Yijian Huang, et al.
Cancer Medicine|April 25, 2022
Germline mutations in penetrant cancer predisposition genes are rare in men with prostate cancer selecting active surveillanceLauren Brady, Lisa F Newcomb, Kehao Zhu, et al.
JAMA|May 30, 2024
Long-Term Outcomes in Patients Using Protocol-Directed Active Surveillance for Prostate CancerLisa F Newcomb, Jeannette M Schenk, Yingye Zheng, et al.
The Prostate|June 22, 2016
Loss of Expression of AZGP1 Is Associated With Worse Clinical Outcomes in a Multi-Institutional Radical Prostatectomy CohortJames D Brooks, Wei Wei, Jonathan R Pollack, et al.
Scientific Reports|January 4, 2024
High expression of Trop2 is associated with aggressive localized prostate cancer and is a candidate urinary biomarkerShiqin Liu, Sarah J Hawley, Christian A Kunder, et al.
The American Journal of Surgical Pathology|September 17, 2016
Histologic Grading of Prostatic Adenocarcinoma Can Be Further Optimized: Analysis of the Relative Prognostic Strength of Individual Architectural Patterns in 1275 Patients From the Canary Retrospective CohortJesse K McKenney, Wei Wei, Sarah Hawley, et al.
Histopathology|June 3, 2024
Proposal for an optimised definition of adverse pathology (unfavourable histology) that predicts metastatic risk in prostatic adenocarcinoma independent of grade group and pathological stageJane K Nguyen, Lara R Harik, Eric A Klein, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 11, 2022
Analysis of separate training and validation radical prostatectomy cohorts identifies 0.25 mm diameter as an optimal definition for "large" cribriform prostatic adenocarcinomaEmily Chan, Jesse K McKenney, Sarah Hawley, et al.
Pageof 7

Showing results (31-40 of 62) with videos related to

Sort By:
Pageof 7
The Journal of Urology|April 30, 2025
Magnetic Resonance Imaging at Second Surveillance Biopsy After Diagnosis in Patients With Grade Group 1 Prostate Cancer in the Canary Prostate Active Surveillance StudyMeera R Chappidi, Lisa F Newcomb, Yingye Zheng, et al.
Cancer|September 13, 2021
Treatment in the absence of disease reclassification among men on active surveillance for prostate cancerPeter S Kirk, Kehao Zhu, Yingye Zheng, et al.
The Journal of Urology|July 13, 2022
Impact of Prostate Health Index Results for Prediction of Biopsy Grade Reclassification During Active SurveillanceChristopher P Filson, Kehao Zhu, Yijian Huang, et al.
Cancer Medicine|April 25, 2022
Germline mutations in penetrant cancer predisposition genes are rare in men with prostate cancer selecting active surveillanceLauren Brady, Lisa F Newcomb, Kehao Zhu, et al.
JAMA|May 30, 2024
Long-Term Outcomes in Patients Using Protocol-Directed Active Surveillance for Prostate CancerLisa F Newcomb, Jeannette M Schenk, Yingye Zheng, et al.
The Prostate|June 22, 2016
Loss of Expression of AZGP1 Is Associated With Worse Clinical Outcomes in a Multi-Institutional Radical Prostatectomy CohortJames D Brooks, Wei Wei, Jonathan R Pollack, et al.
Scientific Reports|January 4, 2024
High expression of Trop2 is associated with aggressive localized prostate cancer and is a candidate urinary biomarkerShiqin Liu, Sarah J Hawley, Christian A Kunder, et al.
The American Journal of Surgical Pathology|September 17, 2016
Histologic Grading of Prostatic Adenocarcinoma Can Be Further Optimized: Analysis of the Relative Prognostic Strength of Individual Architectural Patterns in 1275 Patients From the Canary Retrospective CohortJesse K McKenney, Wei Wei, Sarah Hawley, et al.
Histopathology|June 3, 2024
Proposal for an optimised definition of adverse pathology (unfavourable histology) that predicts metastatic risk in prostatic adenocarcinoma independent of grade group and pathological stageJane K Nguyen, Lara R Harik, Eric A Klein, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 11, 2022
Analysis of separate training and validation radical prostatectomy cohorts identifies 0.25 mm diameter as an optimal definition for "large" cribriform prostatic adenocarcinomaEmily Chan, Jesse K McKenney, Sarah Hawley, et al.
Pageof 7